Mobile Application to Collect PRO Data in NET Patients
ConditionNeuroendocrine Neoplasms (Tumours)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorKing's College Hospital NHS Trust
About this trial
Observational trial to assess the feasibility of monitoring patient reporting symptoms via mobile devices
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Histologically confirmed diagnosis of a NET
Planned treatment for NET
Able to give informed consent
Able to understand the language of the questionnaires
Disqualifiers
Concurrent malignancies for which they are undergoing treatment
No smartphone / device
Any physical, psychological or comprehension problems that prevents completion of questionnaires.
Trial population
Patients with a diagnosis of neuroendocrine neoplasm who are due to undergo one of the following treatments: chemotherapy, everolimus, sunitinib, somatostatin analogues, peptide receptor targeted therapy, embolization/ ablative therapies or surgery.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
2,000 Participants
are grouped into 1 trial groupGroup A: Neuroendocrine neoplasms (tumours)
Trial outcomes
Primary outcomes
1
Reporting compliance
The primary endpoint is patient reporting compliance, defined as the number of days with any patient report submitted during the course of treatment. This will be unique to each course of therapy since they have different durations of treatment.
Time frame
4 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
King's College Hospital NHS Trust
Lead sponsor
Ampersand Health Ltd
Collaborator
Neuroendocrine Cancer UK
Collaborator
Source ClinicalTrials.gov